| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026373629 |
| P356 | DOI | 10.1186/AR1222 |
| P932 | PMC publication ID | 546289 |
| P698 | PubMed publication ID | 15380033 |
| P5875 | ResearchGate publication ID | 8334948 |
| P2093 | author name string | Anne Davidson | |
| Meera Ramanujam | |||
| P2860 | cites work | Synthesis and release of B-lymphocyte stimulator from myeloid cells | Q73335981 |
| TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice | Q74108088 | ||
| Lymphoid neogenesis in rheumatoid synovitis | Q74147962 | ||
| TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS | Q74419758 | ||
| Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity | Q74433998 | ||
| Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells | Q74460576 | ||
| BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex | Q79313873 | ||
| TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 | ||
| DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF | Q24309087 | ||
| APRIL modulates B and T cell immunity | Q24552299 | ||
| BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2 | Q27639845 | ||
| BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 | ||
| Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator | Q28183674 | ||
| BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases | Q28205999 | ||
| DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL | Q28216755 | ||
| APRIL-deficient mice have normal immune system development | Q28511017 | ||
| BCMA is essential for the survival of long-lived bone marrow plasma cells | Q28587037 | ||
| Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice | Q28587370 | ||
| Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. | Q33951524 | ||
| B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". | Q33996226 | ||
| Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome | Q34108411 | ||
| Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor | Q34178508 | ||
| BAFF AND APRIL: a tutorial on B cell survival | Q34994661 | ||
| BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. | Q35140484 | ||
| TWE-PRIL; a fusion protein of TWEAK and APRIL | Q35557596 | ||
| Peripheral B-cell maturation: the intersection of selection and homeostasis | Q35666676 | ||
| Pathogenic roles of B cells in human autoimmunity; insights from the clinic | Q35772863 | ||
| Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response | Q36368953 | ||
| Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations | Q36375661 | ||
| G-CSF-stimulated neutrophils are a prominent source of functional BLyS | Q41818295 | ||
| Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells | Q42079747 | ||
| Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. | Q44223059 | ||
| Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. | Q44471579 | ||
| Engineering an APRIL-specific B cell maturation antigen | Q44756940 | ||
| Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis | Q46397162 | ||
| Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function | Q47283207 | ||
| Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 | ||
| BAFF production by antigen-presenting cells provides T cell co-stimulation. | Q51025017 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice | Q52078930 | ||
| Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. | Q52114309 | ||
| Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus | Q56903374 | ||
| An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway | Q57230082 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peptide | Q172847 |
| membrane protein | Q423042 | ||
| blood proteins | Q425056 | ||
| cell surface receptor | Q2476074 | ||
| autoimmune disease | Q8084905 | ||
| tumor necrosis factor | Q21173843 | ||
| P304 | page(s) | 197-202 | |
| P577 | publication date | 2004-07-29 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | The current status of targeting BAFF/BLyS for autoimmune diseases | |
| P478 | volume | 6 |
| Q30482886 | Apoptosis-related genes change their expression with age and hearing loss in the mouse cochlea |
| Q36158684 | B cells as a therapeutic target in autoimmune diseases |
| Q33573335 | BAFF mediates splenic B cell response and antibody production in experimental Chagas disease. |
| Q87115803 | BAFF regulates activation of self-reactive T cells through B-cell dependent mechanisms and mediates protection in NOD mice |
| Q37236244 | CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. |
| Q36993221 | Developments in the scientific understanding of lupus |
| Q33373525 | High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura |
| Q33380975 | Prevention of murine antiphospholipid syndrome by BAFF blockade |
| Q34350295 | Similarities and differences between selective and nonselective BAFF blockade in murine SLE |
| Q37060593 | Targeting of the immune system in systemic lupus erythematosus |
| Q36321299 | The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome |
| Q24681044 | The future of biologic agents in the treatment of Sjögren's syndrome |
| Q34514923 | The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus |
| Q56902282 | [New therapeutic approaches to autoimmune diseases] |
Search more.